



APR 17 2000

TECH CENTER 1600/2900

RECEIVED

APR 21 2000

PATENT

ATTORNEY DOCKET NO. 50013/002003

Certificate of Mailing: Date of Deposit: April 10, 2000

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231.

Mary Jane DiPalma

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Philip E. Branton et al.

Art Unit: 1633

Serial No.: 09/214,478

Examiner: S. Chen

Filed: June 7, 1999

Title: ADENOVIRUS E4 PROTEINS FOR INDUCING CELL DEATH

Assistant Commissioner For Patents  
Washington, D.C. 20231

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

In reply to the Notice To Comply mailed April 3, 2000, Applicant submits the following:

- ☒ An initial paper copy of the sequence listing to be inserted at the end of the application.
- ☒ An initial copy of the sequence listing in computer readable form.
- ☒ A statement that the contents of the paper and computer readable copies are the same and contain no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

April 10, 2000

Kristina Bieker-Brady, Ph.D.  
Reg. No. 39,109

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045

\\Ntserver\documents\50013\50013.002003 Reply to Notice to Comply.wpd



Application N. : 09/214,478

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: \_\_\_\_\_

**Applicant Must Provide:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**



RECEIVED

APR 21 2000

ATTORNEY DOCKET NO. 50043/002003

4/9  
K. A. Davis  
04-22-00

Certificate of Mailing: Date of Deposit: April 10, 2000

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231.

Mary Jane DiPalma

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Philip E. Branton et al.

Art Unit: 1633

Serial No.: 09/214,478

Examiner: S. Chen

Filed: June 7, 1999

Title: ADENOVIRUS E4 PROTEINS FOR INDUCING CELL DEATH

Assistant Commissioner For Patents

Washington, D.C. 20231

STATEMENT UNDER 37 CFR §1.821

As part of the patent application filed on June 7, 1999, enclosed is a sequence listing in accordance with the requirements of 37 CFR §§1.821 through 1.825 and consisting of three pages.

As required by 37 CFR 1.821(c), the sequence listing appears as a separate part of the application and is found after the Combined Declaration and Power of Attorney. Each sequence in the application appears separately in the sequence listing. And each sequence in the sequence listing is assigned a separate sequence identifier.

As required by 37 CFR §1.821(d), the sequence identifiers are used throughout the application description and claims to refer to their respective sequences.

As required by 37 CFR 1.821(e), enclosed is a diskette containing a copy of the sequence listing in computer readable form.

As required by 37 CFR §1.821(f), I hereby state that the contents of the computer readable form are the same as the contents of the paper copy.

As required by 37 CFR §1.821(g), I hereby state that this submission contains no new matter.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

*April 19, 2000*

*Kristina Bieker Brady*

Kristina Bieker Brady, Ph.D.

Reg. No. 39,109

Clark & Elbing LLP

176 Federal Street

Boston, MA 02110

Telephone: 617-428-0200

Facsimile: 617-428-7045

\\Ntserver\documents\50013\50013.002003 Sequence Statement.wpd